6Y8K
 
 | | Crystal structure of CD137 in complex with the cyclic peptide BCY10916 | | 分子名称: | 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)tripropan-1-one, 1,2-ETHANEDIOL, ACETATE ION, ... | | 著者 | Upadhyaya, P, Kublin, J, Dods, R, Kristensson, J, Lahdenranta, J, Kleyman, M, Repash, E, Ma, J, Mudd, G, Van Rietschoten, K, Haines, E, Harrison, H, Beswick, P, Chen, L, McDonnell, K, Battula, S, Hurov, K, Keen, N. | | 登録日 | 2020-03-05 | | 公開日 | 2021-02-03 | | 最終更新日 | 2024-01-24 | | 実験手法 | X-RAY DIFFRACTION (2.011 Å) | | 主引用文献 | Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
J Immunother Cancer, 9, 2021
|
|
6FAX
 | | Complex of Human CD40 Ectodomain with Lob 7.4 Fab | | 分子名称: | Lob 7.4 heavy chain, Lob 7.4 light chain, Tumor necrosis factor receptor superfamily member 5 | | 著者 | Orr, C.M, Tews, I, Pearson, A.R. | | 登録日 | 2017-12-18 | | 公開日 | 2018-02-07 | | 最終更新日 | 2024-01-17 | | 実験手法 | X-RAY DIFFRACTION (2.99 Å) | | 主引用文献 | Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Cancer Cell, 33, 2018
|
|
6PE8
 | | Crystal structure of CD40/ABBV-323 FAB complex | | 分子名称: | FAB Heavy chain, FAB Light chain, SULFATE ION, ... | | 著者 | Argiriadi, M.A. | | 登録日 | 2019-06-20 | | 公開日 | 2019-08-14 | | 最終更新日 | 2023-10-11 | | 実験手法 | X-RAY DIFFRACTION (2.84 Å) | | 主引用文献 | CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
BMC Mol Cell Biol, 20, 2019
|
|
6PE9
 | | Crystal Structure of CD40 complexed to FAB516 | | 分子名称: | FAB Heavy chain, FAB Light chain, SULFATE ION, ... | | 著者 | Argiriadi, M.A. | | 登録日 | 2019-06-20 | | 公開日 | 2019-08-14 | | 最終更新日 | 2023-10-11 | | 実験手法 | X-RAY DIFFRACTION (3.13 Å) | | 主引用文献 | CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
BMC Mol Cell Biol, 20, 2019
|
|
7P3I
 | | Crystal structure of human CD40/TNFRSF5 in complex with the anti-CD40 DARPin protein | | 分子名称: | Darpin, SODIUM ION, Tumor necrosis factor receptor superfamily member 5 | | 著者 | Malvezzi, F, Mangold, S, Hospodarsch, T, Reichen, C, Iss, C, Lammens, A, Krapp, S, Domke, C. | | 登録日 | 2021-07-07 | | 公開日 | 2022-04-06 | | 最終更新日 | 2022-05-11 | | 実験手法 | X-RAY DIFFRACTION (2.29 Å) | | 主引用文献 | A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression.
Cancer Immunol Res, 10, 2022
|
|
2UWI
 | | Structure of CrmE, a poxvirus TNF receptor | | 分子名称: | CRME PROTEIN | | 著者 | Graham, S.C, Bahar, M.W, Abrescia, N.G, Smith, G.L, Stuart, D.I, Grimes, J.M. | | 登録日 | 2007-03-22 | | 公開日 | 2007-07-10 | | 最終更新日 | 2019-05-15 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Structure of Crme, a Virus-Encoded Tumour Necrosis Factor Receptor.
J.Mol.Biol., 372, 2007
|
|
7D4B
 | | Crystal structure of 4-1BB in complex with a VHH | | 分子名称: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, ... | | 著者 | Wang, C. | | 登録日 | 2020-09-23 | | 公開日 | 2021-07-14 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (3.14 Å) | | 主引用文献 | Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
J Immunother Cancer, 9, 2021
|
|
6T3J
 | | Dual Epitope Targeting by Anti-DR5 Antibodies | | 分子名称: | IgG1-hDR5-01-Heavy Chain, IgG1-hDR5-01-Light Chain, IgG1-hDR5-05-Heavy Chain, ... | | 著者 | Tauchert, M.J, Augustin, M, Krapp, S, Overdijk, M.B, Breij, E.C.W, Hibbert, R.G. | | 登録日 | 2019-10-11 | | 公開日 | 2020-09-16 | | 最終更新日 | 2020-10-14 | | 実験手法 | X-RAY DIFFRACTION (3.05 Å) | | 主引用文献 | Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
Mol.Cancer Ther., 19, 2020
|
|
1ZA3
 | | The crystal structure of the YSd1 Fab bound to DR5 | | 分子名称: | Fab-YSd1 heavy chain, Fab-YSd1 light chain, Tumor necrosis factor receptor superfamily member 10B | | 著者 | Fellouse, F.A, Li, B, Compaan, D.M, Peden, A.A, Hymowitz, S.G, Sidhu, S.S. | | 登録日 | 2005-04-05 | | 公開日 | 2005-06-14 | | 最終更新日 | 2023-08-23 | | 実験手法 | X-RAY DIFFRACTION (3.35 Å) | | 主引用文献 | Molecular recognition by a binary code.
J.Mol.Biol., 348, 2005
|
|
2AW2
 | | Crystal structure of the human BTLA-HVEM complex | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, B and T lymphocyte attenuator, NICKEL (II) ION, ... | | 著者 | Compaan, D.M, Gonzalez, L.C, Tom, I, Loyet, K.M, Eaton, D, Hymowitz, S.G. | | 登録日 | 2005-08-31 | | 公開日 | 2005-09-27 | | 最終更新日 | 2023-08-23 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Attenuating Lymphocyte Activity: the crystal structure of the BTLA-HVEM complex
J.Biol.Chem., 280, 2005
|
|
5IHL
 | |
7YK4
 | | ox40-antibody | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Tumor necrosis factor receptor superfamily member 4, antibody-H, ... | | 著者 | Zhou, A. | | 登録日 | 2022-07-21 | | 公開日 | 2023-08-09 | | 実験手法 | X-RAY DIFFRACTION (2.7 Å) | | 主引用文献 | Structural Basis of a Novel Agonistic Anti-OX40 Antibody.
Biomolecules, 12, 2022
|
|
1NCF
 | |
7YXU
 | | Crystal structure of agonistic antibody 1618 fab domain bound to human 4-1BB. | | 分子名称: | MANGANESE (II) ION, Tumor necrosis factor receptor superfamily member 9, heavy chain of Fab, ... | | 著者 | Hakansson, M, Rose, N, Petersson, J, Enell Smith, K, Thorolfsson, M, von Schantz, L. | | 登録日 | 2022-02-16 | | 公開日 | 2023-01-25 | | 最終更新日 | 2024-02-07 | | 実験手法 | X-RAY DIFFRACTION (2.31 Å) | | 主引用文献 | The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Mol.Cancer Ther., 22, 2023
|
|
3WVT
 | |
3X3F
 | |
8GYE
 | |
8YX9
 | | CD40 in complex with Dacetuzumab Fab | | 分子名称: | Dacetuzumab, Heavy chain, light chain, ... | | 著者 | Caaveiro, J.M.M, Fernandez-Perez, J, Tsumoto, K. | | 登録日 | 2024-04-02 | | 公開日 | 2024-05-08 | | 最終更新日 | 2024-05-22 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab.
Biochem.Biophys.Res.Commun., 714, 2024
|
|
8YX1
 | | CD40 in complex with Bleselumab Fab | | 分子名称: | Bleselumab, heavy chain, light chain, ... | | 著者 | Caaveiro, J.M.M, Fernandez-Perez, J, Tsumoto, K. | | 登録日 | 2024-04-01 | | 公開日 | 2024-05-08 | | 最終更新日 | 2024-05-22 | | 実験手法 | X-RAY DIFFRACTION (2.7 Å) | | 主引用文献 | Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab.
Biochem.Biophys.Res.Commun., 714, 2024
|
|
8DS5
 | | X-ray structure of the MK5890 Fab - CD27 antibody-antigen complex | | 分子名称: | CADMIUM ION, CD27 antigen, MK-5890 Fab heavy chain, ... | | 著者 | Fischmann, T.O. | | 登録日 | 2022-07-21 | | 公開日 | 2022-09-28 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (1.926 Å) | | 主引用文献 | Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
J Immunother Cancer, 10, 2022
|
|
6A3W
 | | Complex structure of 4-1BB and utomilumab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Tumor necrosis factor receptor superfamily member 9, utomilumab VH, ... | | 著者 | Li, Y, Tan, S, Zhang, C, Chai, Y, Qi, J, Tien, P, Gao, S, Gao, G.F. | | 登録日 | 2018-06-17 | | 公開日 | 2018-10-10 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab.
Cell Rep, 25, 2018
|
|
8AG1
 | | Crystal structure of a novel OX40 antibody | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Novel OX40 antibody heavy chain, Novel OX40 antibody light chain, ... | | 著者 | Gao, H, Zhou, A. | | 登録日 | 2022-07-19 | | 公開日 | 2023-07-19 | | 最終更新日 | 2024-02-07 | | 実験手法 | X-RAY DIFFRACTION (3.303 Å) | | 主引用文献 | Structural Basis of a Novel Agonistic Anti-OX40 Antibody.
Biomolecules, 12, 2022
|
|
8DPX
 | | Preligand association structure of DR5 | | 分子名称: | Tumor necrosis factor receptor superfamily member 10B | | 著者 | Du, G, Zhao, L, Chou, J.J. | | 登録日 | 2022-07-17 | | 公開日 | 2023-02-15 | | 実験手法 | SOLUTION NMR | | 主引用文献 | Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation.
Cell Res., 33, 2023
|
|
8OZ3
 | | Crystal structure of scFv ATOR 1017 bound to human 4-1BB | | 分子名称: | Single chain Fv, Tumor necrosis factor receptor superfamily member 9 | | 著者 | Hakansson, M, Von Schantz, L, Rose, N. | | 登録日 | 2023-05-08 | | 公開日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (3.1 Å) | | 主引用文献 | ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Cancer Immunol.Immunother., 72, 2023
|
|
8P6Q
 | | Racemic structure of TNFR1 cysteine-rich domain | | 分子名称: | D-TNFR-1 CRD2, SULFATE ION, Tumor necrosis factor-binding protein 1 | | 著者 | Lander, A.J, Jin, Y, Luk, L.Y.P. | | 登録日 | 2023-05-28 | | 公開日 | 2024-01-24 | | 最終更新日 | 2024-03-06 | | 実験手法 | X-RAY DIFFRACTION (1.4 Å) | | 主引用文献 | Deciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and d-Peptide Ligand Discovery.
Acs Bio Med Chem Au, 4, 2024
|
|
